Angelina Jolie's case highlights the importance of knowing …
Treating breast cancer almost always involves surgery, and for …
A group of more than 120 cancer researchers and physicians took…
Updated: Wednesday, 28 Nov 2012, 5:04 PM EST
Published : Wednesday, 28 Nov 2012, 5:04 PM EST
CAMBRIDGE, Mass. (AP) - Aveo Oncology said Wednesday that the Food and Drug Administration will complete a review of its cancer pill Tivopath by July 28.
Aveo and its partner Astellas Pharma Inc. want to market Tivopath as a treatment for advanced kidney cancer. The companies said the FDA accepted their application, and the agency will conduct a standard 10-month review. Astellas will pay Aveo $15 million now that the filing has been accepted.
Tivopath, or tivozanib, is a tablet intended to be taken once per day. The companies are also studying the drug as a treatment for other solid tumors, including cancers of the breast and colon.
Ground rules for posting comments: No profanity or personal attacks. No racially charged comments. If it's not something you would say to someone's face, it's most likely inappropriate. Please comment on the subject of the story itself. If you do not follow these rules, we will remove your post. Repeat offenders will be banned from making future comments. Keep it civil, folks! WANE is not responsible for the content posted in this comment section.